Recent breakthroughs harness artificial intelligence to transform drug discovery and cancer prognosis. Nanyang Biologics plans a $1.5 billion Nasdaq SPAC combining machine learning with natural compound libraries for accelerated therapeutic development. Separately, a new ANN and hyperspectral imaging approach enhances prognostication in esophageal adenocarcinoma, providing improved predictive insights from histopathological specimens. Additionally, a CRISP framework enables drug response prediction at single-cell resolution in previously untested cell types, offering precision tools for drug repurposing and therapy optimization.